The global market for Neuromyelitis Optica Drug was valued at US$ 49.8 million in the year 2024 and is projected to reach a revised size of US$ 61.1 million by 2031, growing at a CAGR of 3.0% during the forecast period.

Neuromyelitis Optica Drug Market

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren"t yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.

The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.

This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Drug.

The Neuromyelitis Optica Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neuromyelitis Optica Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Neuromyelitis Optica Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Neuromyelitis Optica Drug Market Report

Report Metric	Details
Report Name	Neuromyelitis Optica Drug Market
Accounted market size in year	US$ 49.8 million
Forecasted market size in 2031	US$ 61.1 million
CAGR	3.0%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Glucocorticoids Immunotherapies Others
Segment by Application	Acute Attack Remission Prophylactic Treatment
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuromyelitis Optica Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Neuromyelitis Optica Drug Market growing?

Ans: The Neuromyelitis Optica Drug Market witnessing a CAGR of 3.0% during the forecast period 2025-2031.

What is the Neuromyelitis Optica Drug Market size in 2031?

Ans: The Neuromyelitis Optica Drug Market size in 2031 will be US$ 61.1 million.

What is the Neuromyelitis Optica Drug Market share by region?

Ans: Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.

What is the market share of major companies in Neuromyelitis Optica Drug Market?

Ans: Top 3 companies occupied about 35% market share.

Who are the main players in the Neuromyelitis Optica Drug Market report?

Ans: The main players in the Neuromyelitis Optica Drug Market are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP

What are the Application segmentation covered in the Neuromyelitis Optica Drug Market report?

Ans: The Applications covered in the Neuromyelitis Optica Drug Market report are Acute Attack, Remission Prophylactic Treatment

What are the Type segmentation covered in the Neuromyelitis Optica Drug Market report?

Ans: The Types covered in the Neuromyelitis Optica Drug Market report are Glucocorticoids, Immunotherapies, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Glucocorticoids

1.2.3 Immunotherapies

1.2.4 Others

1.3 Market by Application

1.3.1 Global Neuromyelitis Optica Drug Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Acute Attack

1.3.3 Remission Prophylactic Treatment

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Neuromyelitis Optica Drug Market Perspective (2020-2031)

2.2 Global Neuromyelitis Optica Drug Growth Trends by Region

2.2.1 Global Neuromyelitis Optica Drug Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Neuromyelitis Optica Drug Historic Market Size by Region (2020-2025)

2.2.3 Neuromyelitis Optica Drug Forecasted Market Size by Region (2026-2031)

2.3 Neuromyelitis Optica Drug Market Dynamics

2.3.1 Neuromyelitis Optica Drug Industry Trends

2.3.2 Neuromyelitis Optica Drug Market Drivers

2.3.3 Neuromyelitis Optica Drug Market Challenges

2.3.4 Neuromyelitis Optica Drug Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Neuromyelitis Optica Drug Players by Revenue

3.1.1 Global Top Neuromyelitis Optica Drug Players by Revenue (2020-2025)

3.1.2 Global Neuromyelitis Optica Drug Revenue Market Share by Players (2020-2025)

3.2 Global Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Neuromyelitis Optica Drug Revenue

3.4 Global Neuromyelitis Optica Drug Market Concentration Ratio

3.4.1 Global Neuromyelitis Optica Drug Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Drug Revenue in 2024

3.5 Global Key Players of Neuromyelitis Optica Drug Head office and Area Served

3.6 Global Key Players of Neuromyelitis Optica Drug, Product and Application

3.7 Global Key Players of Neuromyelitis Optica Drug, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Neuromyelitis Optica Drug Breakdown Data by Type

4.1 Global Neuromyelitis Optica Drug Historic Market Size by Type (2020-2025)

4.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2026-2031)

5 Neuromyelitis Optica Drug Breakdown Data by Application

5.1 Global Neuromyelitis Optica Drug Historic Market Size by Application (2020-2025)

5.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Neuromyelitis Optica Drug Market Size (2020-2031)

6.2 North America Neuromyelitis Optica Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Neuromyelitis Optica Drug Market Size by Country (2020-2025)

6.4 North America Neuromyelitis Optica Drug Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Neuromyelitis Optica Drug Market Size (2020-2031)

7.2 Europe Neuromyelitis Optica Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Neuromyelitis Optica Drug Market Size by Country (2020-2025)

7.4 Europe Neuromyelitis Optica Drug Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Neuromyelitis Optica Drug Market Size (2020-2031)

8.2 Asia-Pacific Neuromyelitis Optica Drug Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2020-2025)

8.4 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Neuromyelitis Optica Drug Market Size (2020-2031)

9.2 Latin America Neuromyelitis Optica Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Neuromyelitis Optica Drug Market Size by Country (2020-2025)

9.4 Latin America Neuromyelitis Optica Drug Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Neuromyelitis Optica Drug Market Size (2020-2031)

10.2 Middle East & Africa Neuromyelitis Optica Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2020-2025)

10.4 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Details

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Neuromyelitis Optica Drug Introduction

11.1.4 Pfizer Revenue in Neuromyelitis Optica Drug Business (2020-2025)

11.1.5 Pfizer Recent Development

11.2 Fresenius

11.2.1 Fresenius Company Details

11.2.2 Fresenius Business Overview

11.2.3 Fresenius Neuromyelitis Optica Drug Introduction

11.2.4 Fresenius Revenue in Neuromyelitis Optica Drug Business (2020-2025)

11.2.5 Fresenius Recent Development

11.3 Teva

11.3.1 Teva Company Details

11.3.2 Teva Business Overview

11.3.3 Teva Neuromyelitis Optica Drug Introduction

11.3.4 Teva Revenue in Neuromyelitis Optica Drug Business (2020-2025)

11.3.5 Teva Recent Development

11.4 Sandoz

11.4.1 Sandoz Company Details

11.4.2 Sandoz Business Overview

11.4.3 Sandoz Neuromyelitis Optica Drug Introduction

11.4.4 Sandoz Revenue in Neuromyelitis Optica Drug Business (2020-2025)

11.4.5 Sandoz Recent Development

11.5 Intas

11.5.1 Intas Company Details

11.5.2 Intas Business Overview

11.5.3 Intas Neuromyelitis Optica Drug Introduction

11.5.4 Intas Revenue in Neuromyelitis Optica Drug Business (2020-2025)

11.5.5 Intas Recent Development

11.6 Gyjtrs

11.6.1 Gyjtrs Company Details

11.6.2 Gyjtrs Business Overview

11.6.3 Gyjtrs Neuromyelitis Optica Drug Introduction

11.6.4 Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2020-2025)

11.6.5 Gyjtrs Recent Development

11.7 NANG KUANG

11.7.1 NANG KUANG Company Details

11.7.2 NANG KUANG Business Overview

11.7.3 NANG KUANG Neuromyelitis Optica Drug Introduction

11.7.4 NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2020-2025)

11.7.5 NANG KUANG Recent Development

11.8 Tianjin Kingyork

11.8.1 Tianjin Kingyork Company Details

11.8.2 Tianjin Kingyork Business Overview

11.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Introduction

11.8.4 Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2020-2025)

11.8.5 Tianjin Kingyork Recent Development

11.9 Baxter

11.9.1 Baxter Company Details

11.9.2 Baxter Business Overview

11.9.3 Baxter Neuromyelitis Optica Drug Introduction

11.9.4 Baxter Revenue in Neuromyelitis Optica Drug Business (2020-2025)

11.9.5 Baxter Recent Development

11.10 CSL

11.10.1 CSL Company Details

11.10.2 CSL Business Overview

11.10.3 CSL Neuromyelitis Optica Drug Introduction

11.10.4 CSL Revenue in Neuromyelitis Optica Drug Business (2020-2025)

11.10.5 CSL Recent Development

11.11 Grifols

11.11.1 Grifols Company Details

11.11.2 Grifols Business Overview

11.11.3 Grifols Neuromyelitis Optica Drug Introduction

11.11.4 Grifols Revenue in Neuromyelitis Optica Drug Business (2020-2025)

11.11.5 Grifols Recent Development

11.12 Octapharma

11.12.1 Octapharma Company Details

11.12.2 Octapharma Business Overview

11.12.3 Octapharma Neuromyelitis Optica Drug Introduction

11.12.4 Octapharma Revenue in Neuromyelitis Optica Drug Business (2020-2025)

11.12.5 Octapharma Recent Development

11.13 CBOP

11.13.1 CBOP Company Details

11.13.2 CBOP Business Overview

11.13.3 CBOP Neuromyelitis Optica Drug Introduction

11.13.4 CBOP Revenue in Neuromyelitis Optica Drug Business (2020-2025)

11.13.5 CBOP Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Neuromyelitis Optica Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Glucocorticoids

Table 3. Key Players of Immunotherapies

Table 4. Key Players of Others

Table 5. Global Neuromyelitis Optica Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Neuromyelitis Optica Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Neuromyelitis Optica Drug Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global Neuromyelitis Optica Drug Market Share by Region (2020-2025)

Table 9. Global Neuromyelitis Optica Drug Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global Neuromyelitis Optica Drug Market Share by Region (2026-2031)

Table 11. Neuromyelitis Optica Drug Market Trends

Table 12. Neuromyelitis Optica Drug Market Drivers

Table 13. Neuromyelitis Optica Drug Market Challenges

Table 14. Neuromyelitis Optica Drug Market Restraints

Table 15. Global Neuromyelitis Optica Drug Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global Neuromyelitis Optica Drug Market Share by Players (2020-2025)

Table 17. Global Top Neuromyelitis Optica Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2024)

Table 18. Ranking of Global Top Neuromyelitis Optica Drug Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by Neuromyelitis Optica Drug Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of Neuromyelitis Optica Drug, Headquarters and Area Served

Table 21. Global Key Players of Neuromyelitis Optica Drug, Product and Application

Table 22. Global Key Players of Neuromyelitis Optica Drug, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Neuromyelitis Optica Drug Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2020-2025)

Table 26. Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2026-2031)

Table 28. Global Neuromyelitis Optica Drug Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2020-2025)

Table 30. Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2026-2031)

Table 32. North America Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America Neuromyelitis Optica Drug Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America Neuromyelitis Optica Drug Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe Neuromyelitis Optica Drug Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe Neuromyelitis Optica Drug Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific Neuromyelitis Optica Drug Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America Neuromyelitis Optica Drug Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America Neuromyelitis Optica Drug Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa Neuromyelitis Optica Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2026-2031) & (US$ Million)

Table 47. Pfizer Company Details

Table 48. Pfizer Business Overview

Table 49. Pfizer Neuromyelitis Optica Drug Product

Table 50. Pfizer Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)

Table 51. Pfizer Recent Development

Table 52. Fresenius Company Details

Table 53. Fresenius Business Overview

Table 54. Fresenius Neuromyelitis Optica Drug Product

Table 55. Fresenius Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)

Table 56. Fresenius Recent Development

Table 57. Teva Company Details

Table 58. Teva Business Overview

Table 59. Teva Neuromyelitis Optica Drug Product

Table 60. Teva Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)

Table 61. Teva Recent Development

Table 62. Sandoz Company Details

Table 63. Sandoz Business Overview

Table 64. Sandoz Neuromyelitis Optica Drug Product

Table 65. Sandoz Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)

Table 66. Sandoz Recent Development

Table 67. Intas Company Details

Table 68. Intas Business Overview

Table 69. Intas Neuromyelitis Optica Drug Product

Table 70. Intas Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)

Table 71. Intas Recent Development

Table 72. Gyjtrs Company Details

Table 73. Gyjtrs Business Overview

Table 74. Gyjtrs Neuromyelitis Optica Drug Product

Table 75. Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)

Table 76. Gyjtrs Recent Development

Table 77. NANG KUANG Company Details

Table 78. NANG KUANG Business Overview

Table 79. NANG KUANG Neuromyelitis Optica Drug Product

Table 80. NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)

Table 81. NANG KUANG Recent Development

Table 82. Tianjin Kingyork Company Details

Table 83. Tianjin Kingyork Business Overview

Table 84. Tianjin Kingyork Neuromyelitis Optica Drug Product

Table 85. Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)

Table 86. Tianjin Kingyork Recent Development

Table 87. Baxter Company Details

Table 88. Baxter Business Overview

Table 89. Baxter Neuromyelitis Optica Drug Product

Table 90. Baxter Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)

Table 91. Baxter Recent Development

Table 92. CSL Company Details

Table 93. CSL Business Overview

Table 94. CSL Neuromyelitis Optica Drug Product

Table 95. CSL Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)

Table 96. CSL Recent Development

Table 97. Grifols Company Details

Table 98. Grifols Business Overview

Table 99. Grifols Neuromyelitis Optica Drug Product

Table 100. Grifols Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)

Table 101. Grifols Recent Development

Table 102. Octapharma Company Details

Table 103. Octapharma Business Overview

Table 104. Octapharma Neuromyelitis Optica Drug Product

Table 105. Octapharma Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)

Table 106. Octapharma Recent Development

Table 107. CBOP Company Details

Table 108. CBOP Business Overview

Table 109. CBOP Neuromyelitis Optica Drug Product

Table 110. CBOP Revenue in Neuromyelitis Optica Drug Business (2020-2025) & (US$ Million)

Table 111. CBOP Recent Development

Table 112. Research Programs/Design for This Report

Table 113. Key Data Information from Secondary Sources

Table 114. Key Data Information from Primary Sources

Table 115. Authors List of This Report

List of Figures

Figure 1. Neuromyelitis Optica Drug Picture

Figure 2. Global Neuromyelitis Optica Drug Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Neuromyelitis Optica Drug Market Share by Type: 2024 VS 2031

Figure 4. Glucocorticoids Features

Figure 5. Immunotherapies Features

Figure 6. Others Features

Figure 7. Global Neuromyelitis Optica Drug Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global Neuromyelitis Optica Drug Market Share by Application: 2024 VS 2031

Figure 9. Acute Attack Case Studies

Figure 10. Remission Prophylactic Treatment Case Studies

Figure 11. Neuromyelitis Optica Drug Report Years Considered

Figure 12. Global Neuromyelitis Optica Drug Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Neuromyelitis Optica Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Neuromyelitis Optica Drug Market Share by Region: 2024 VS 2031

Figure 15. Global Neuromyelitis Optica Drug Market Share by Players in 2024

Figure 16. Global Top Neuromyelitis Optica Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2024)

Figure 17. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Drug Revenue in 2024

Figure 18. North America Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America Neuromyelitis Optica Drug Market Share by Country (2020-2031)

Figure 20. United States Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Neuromyelitis Optica Drug Market Share by Country (2020-2031)

Figure 24. Germany Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Neuromyelitis Optica Drug Market Share by Region (2020-2031)

Figure 32. China Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Neuromyelitis Optica Drug Market Share by Country (2020-2031)

Figure 40. Mexico Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Neuromyelitis Optica Drug Market Share by Country (2020-2031)

Figure 44. Turkey Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE Neuromyelitis Optica Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Pfizer Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)

Figure 48. Fresenius Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)

Figure 49. Teva Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)

Figure 50. Sandoz Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)

Figure 51. Intas Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)

Figure 52. Gyjtrs Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)

Figure 53. NANG KUANG Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)

Figure 54. Tianjin Kingyork Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)

Figure 55. Baxter Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)

Figure 56. CSL Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)

Figure 57. Grifols Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)

Figure 58. Octapharma Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)

Figure 59. CBOP Revenue Growth Rate in Neuromyelitis Optica Drug Business (2020-2025)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions